Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease

Abstract

Butyrate decreases proinflammatory cytokine expression via inhibition of NFkappaB activation and IkappaBalpha degradation. These anti-inflammatory properties provide a rationale for assessing butyrate in the treatment of CD.